Nasdaq
$1.44▼ 0.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $259.7MShares out 1.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 10.2Pre-market26.10.02 21:188-KKey event#●●●#●●●#●●●
Century Therapeutics, Inc.Bullish
Century Therapeutics presented nonclinical data for its type 1 diabetes candidate, CNTY-813, at the EASD meeting on October 2, 2026. The data demonstrated the immune evasion and glycemic control capabilities of the Allo-Evasion 5.0-engineered therapy, and the company remains on track to submit an IND in Q4 2026. Initial clinical data from the first-in-human study are anticipated in the second half of 2027.…more
$1.44-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.15After-hours26.09.16 07:254Ownership
Century Therapeutics, Inc.
Century Therapeutics insider Gregory Russotti reported a change in his beneficial ownership of company securities as of September 14, 2026. This filing is a standard Form 4 disclosure regarding insider stock holdings.…more
$1.44-0.35%vs prev closeView filingShare - 9.15After-hours26.09.16 07:254Ownership
Century Therapeutics, Inc.
Century Therapeutics insider Carr Douglas reported a change in beneficial ownership of securities as of September 14, 2026. This filing serves as a standard disclosure of insider equity movement and does not involve any material changes to the company's capital structure or listing status.…more
$1.44-0.35%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:05#●●●#●●●
Century Therapeutics to Attend Jefferies Global Healthcare Conference
Century Therapeutics announced its participation in the upcoming 2026 Jefferies Global Healthcare Conference in London. This is a routine industry event participation and does not provide immediate material impact on the stock.…more
$1.44-0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Pre-market26.10.02 21:05
●●●●●●●● ●●●●● ●●●●●●
Century Therapeutics demonstrated the efficacy and manufacturing consistency of its type 1 diabetes therapy, CNTY-813, through new nonclinical data. The company remains on track to submit an IND application in the fourth quarter of 2026.…more
$1.44-0.35%vs prev close - 9.9After-hours26.09.10 05:05
●●●●●●●● ●●●●● ●●●●●●
Century Therapeutics has appointed biotech industry veteran Joseph Truitt to its Board of Directors. The appointment aims to strengthen leadership as the company advances its key clinical-stage therapeutic programs.…more
$1.44-0.35%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report